34918-57-5

Basic information

• Product Name: Benzeneacetic acid, 3-bromo-4-hydroxy-, methyl ester
• CAS NO: 34918-57-5
• Molecular Formula: C9H9BrO3
• Molecular Weight: 245.073
• Mol File: 34918-57-5.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, 3-bromo-4-hydroxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 3-bromo-4-hydroxy-, methyl ester(34918-57-5)
• EPA Substance Registry System: Benzeneacetic acid, 3-bromo-4-hydroxy-, methyl ester(34918-57-5)

Safety Data

• Hazardous Substances Data: 34918-57-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 38692-80-7 2-(3-bromo-4-hydroxyphenyl)acetic acid 
• 42058-59-3 3-hydroxy-benzeneacetic acid, methyl ester 
• 156-38-7 4-hydroxyphenylacetate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 

Downstream Products

• 544478-37-7 [3-Bromo-4-(3-bromo-propoxy)-phenyl]-acetic acid methyl ester 
• 101111-25-5 methyl 2-(4-(benzyloxy)-3-bromophenyl)acetate 
• 234757-51-8 ethyl 2-(4-(benzyloxy)-3-bromophenyl)acetate 
• 1354633-17-2 C₁₅H₁₈O₅ 
• 1354633-33-2 C₁₅H₁₆O₅ 
• 1354633-20-7 C₁₃H₁₄O₄ 
• 916243-38-4 methyl 2-{4-[(2-bromobenzyl)oxy]-3-(4-hydroxybut-1-yn-1-yl)phenyl}acetate 
• 1354633-53-6 C₂₀H₂₂O₄ 
• 1354633-50-3 C₂₀H₂₀O₄ 
• 916243-39-5 (Z)-methyl 2-[11-(3-hydroxypropylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl]acetate 
• 140462-76-6 olopatadine hydrochloride 
• 100126-08-7 3-Brom-4-methoxymethyloxy-phenylessigsaeure-methylester 
• 19626-36-9 methyl 2-(3-bromo-4-methoxyphenyl)acetate 
• 1422431-62-6 14-(S)-9-benzyloxy-2,3,10-trimethoxytetrahydroprotoberberine 

Relevant articles and documents

Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts

A novel diazaspiro[3.4]octane series was identified from a Plasmodium falciparum whole-cell high-throughput screening campaign. Hits displayed activity against multiple stages of the parasite lifecycle, which together with a novel sp3-rich scaffold provided an attractive starting point for a hit-to-lead medicinal chemistry optimization and biological profiling program. Structure-activity-relationship studies led to the identification of compounds that showed low nanomolar asexual blood-stage activity (50 nM) together with strong gametocyte sterilizing properties that translated to transmission-blocking activity in the standard membrane feeding assay. Mechanistic studies through resistance selection with one of the analogues followed by whole-genome sequencing implicated the P. falciparum cyclic amine resistance locus in the mode of resistance.

Therapeutic use of benzylidene tetrahydropyridine derivatives

The invention belongs to the technical field of pharmaceutical and relates to therapeutic use of benzylidene tetrahydropyridine derivatives, specifically use of berberine derivatives for resisting diabetes, reducing blood fat and cholesterol, and treating cardiovascular diseases, particularly use of resisting diabetes.

DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF

The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.